Author: Jain, Rashi; Mujwar, Somdutt
Title: Repurposing metocurine as main protease inhibitor to develop novel antiviral therapy for COVID-19 Cord-id: ya2br01o Document date: 2020_8_11
ID: ya2br01o
Snippet: The outbreak of severe acute respiratory syndrome coronavirus-2 is causing a serious disaster through coronavirus disease-19 (COVID-19) around the globe. A large segment of the population from every corner of the world is already infected with this dreadful pathogen with a high mortality rate. These numbers are increasing drastically causing a situation of a global pandemic. Although after the continuous scientific efforts, we are still not having any specific drug or vaccine for the SARS-CoV-2
Document: The outbreak of severe acute respiratory syndrome coronavirus-2 is causing a serious disaster through coronavirus disease-19 (COVID-19) around the globe. A large segment of the population from every corner of the world is already infected with this dreadful pathogen with a high mortality rate. These numbers are increasing drastically causing a situation of a global pandemic. Although after the continuous scientific efforts, we are still not having any specific drug or vaccine for the SARS-CoV-2 pathogen to date and there is an urgent need to develop a newer therapy to counter the COVID-19 global pandemic. Thus, in the current study, a framework for computational drug repurposing is established, and based on their safety profile, metocurine was chosen as a safe and effective drug candidate for developing therapy against the viral Mpro enzyme of SARS-CoV-2 for the treatment of COVID-19.
Search related documents:
Co phrase search for related documents- abnormal liver and lymphadenopathy abnormal liver: 1
- acid synthesis and active binding: 1, 2
- acid synthesis and active site: 1, 2
- acid synthesis and acute respiratory syndrome: 1, 2, 3, 4, 5, 6
- active bind site and acute respiratory syndrome: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13
- active binding and acute respiratory syndrome: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
- active binding and additional feature: 1
- active site and acute respiratory syndrome: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
- active site and additional feature: 1
- active site and macromolecular assembly: 1
- acute respiratory syndrome and additional feature: 1, 2
- acute respiratory syndrome and local minima: 1
- acute respiratory syndrome and lung consider: 1, 2, 3
- acute respiratory syndrome and lymphadenopathy abnormal liver: 1
- acute respiratory syndrome and macromolecular assembly: 1
Co phrase search for related documents, hyperlinks ordered by date